Participants in a phase I/II clinical trial of a new enzyme-based treatment for severe dry eye disease experienced reduced signs of disease and discomfort, according to a paper in Translational Vision Science and Technology.
Clinicians who use smartphones to capture photographs of patients' eyes risk misdiagnosis if they base their decisions on objective data extracted from non-calibrated cameras, according to new research published this week in the Nature journal Scientific Reports.
Hoping to earn its share of the $3.5 trillion health care market, the medical industry is pouring more money than ever into advertising its products — from high-priced prescriptions to do-it-yourself genetic tests and unapproved stem cell treatments.
Johns Hopkins researchers report that chronic dry eye, a condition in which natural tears fail to adequately lubricate the eyes, can slow reading rate and significantly disrupt day to day tasks that require visual concentration for long periods of time.
X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 antagonists to improve immune cell trafficking to treat cancer and rare disease, today announced results from a pilot study of X4P-001-IO in combination with Opdivo (nivolumab) in patients with clear cell renal cell carcinoma who are non-responsive to the anti-PD-1 checkpoint inhibitor Opdivo alone.
Sun Pharmaceutical Industries Ltd. today announced that Sun Pharma has received approval for CEQUA (cyclosporine ophthalmic solution) 0.09%, from the U.S. Food and Drug Administration. CEQUA is indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye).
As anyone who has experienced an annoying alternation between dry and watery eyes can confirm, tears alone aren't enough to keep the eye from drying out. A microscopically thin film of oils known as the tear film lipid layer is key to preventing the tear film from evaporating.